• Users Online: 55
  • Print this page
  • Email this page


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 1  |  Page : 35-39

Pharmacological management of chronic obstructive pulmonary disease by low-dose theophylline: A prospective hospital-based study in East Godavari of Andhra Pradesh


1 Department of Pulmonary Medicine, KIMS, Amalapuram, Andhra Pradesh, India
2 Department of Biochemistry, KIMS, Amalapuram, Andhra Pradesh, India

Date of Submission02-Apr-2019
Date of Decision20-Apr-2019
Date of Acceptance29-Sep-2019
Date of Web Publication08-Jan-2020

Correspondence Address:
Dr. Bhargav Prasad Bathula
Department of Pulmonary Medicine, KIMS, Amalapuram, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijrc.ijrc_11_19

Rights and Permissions
  Abstract 


Background: High therapeutic dose of theophylline is not tolerated well by some patients. As it is an effective and affordable drug, the effectiveness of low-dose theophylline in pharmacological management of chronic obstructive pulmonary disease (COPD) was assessed. Aim: The aim of this study was to detect the efficacy of low-dose theophylline in COPD patients. Patients and Methods: Patients with stable COPD were enrolled. The complete blood picture (CBP), pulmonary function tests (PFTs), and St. George's Respiratory Questionnaire (SGRQ) were performed at enrolment. Patients were categorized into two groups: subjects and controls. All the participants were given medication for COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. However, subjects were kept on low-dose sustained-release oral drug theophylline (150 mg twice daily) as an add-on. At every follow-up, once every 10 days up to 30 days, their parameters were recorded. The difference between the prognostic biomarkers was analyzed using the Student's “t”-test. Results: The CBP, SGRQ, and PFTs showed improvement in COPD patients treated with low-dose theophylline, i.e., subject group. Even though the PFTs improved in subjects, evidence of COPD remained. Low-dose theophylline may help to improve the quality of life in COPD patients. Conclusion: As a Cost-effective medication, low-dose theophylline can be used as an add-on drug to GOLD guidelines for the treatment of COPD. The subjects may feel better and can lead their normal life even with COPD.

Keywords: Complete blood picture, pulmonary disease, pulmonary function tests theophylline


How to cite this article:
Bathula BP, Shaik H, Yasovardhan M, Deepthi S K, Bandela PV, Subbarao P. Pharmacological management of chronic obstructive pulmonary disease by low-dose theophylline: A prospective hospital-based study in East Godavari of Andhra Pradesh. Indian J Respir Care 2020;9:35-9

How to cite this URL:
Bathula BP, Shaik H, Yasovardhan M, Deepthi S K, Bandela PV, Subbarao P. Pharmacological management of chronic obstructive pulmonary disease by low-dose theophylline: A prospective hospital-based study in East Godavari of Andhra Pradesh. Indian J Respir Care [serial online] 2020 [cited 2020 Jul 7];9:35-9. Available from: http://www.ijrconline.org/text.asp?2020/9/1/35/275365




  Introduction Top


Theophylline, a xanthine derivative bronchodilator, has been used to treat chronic obstructive pulmonary disease (COPD) for over seven decades. Currently, it has lost popularity because of the introduction of more effective bronchodilators; theophylline is needed in relatively high concentrations (10–20 mg/L). At this high dose, theophylline can relax the human airway smooth muscle by elevating the cyclic adenosine monophosphate levels. Unfortunately, many patients are not able to tolerate high-dose therapeutic concentrations of theophylline. Current studies bring a new insight into the molecular action of low-dose sustained-release theophylline; it can reverse the steroid resistance in COPD and can act as anti-inflammatory drug.[1],[2] Theophylline is recommended when other long-term bronchodilators are not available or patient cannot afford it.

A clinical diagnosis of COPD should be considered in patients having chronic cough, sputum production, and dyspnea and having a history of exposure to risk factors such as smoking or biomass fuel. The presence of postbronchodilator forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) ratio <0.7 confirms the diagnosis of COPD which remains a clinical diagnosis, confirmed by measurement of airflow limitation using spirometry, a postbronchodilator FEV1 <80% (predicted). Although theophylline has effects when used in bronchodilator doses, increasing evidence shows that at low plasma concentrations, it has significant anti-inflammatory effects in COPD.[3]

Inhaled bronchodilators in COPD are central to symptom management and are commonly given on a regular basis to prevent or reduce symptoms. The aim of this study was to assess the effects of low-dose theophylline at 150 mg/day twice, added to long acting β2 agonist (LABA) + long-acting muscarinic antagonists (LAMAs) + inhaled corticosteroids (ICSs) rotahalers. This study was done in accordance with the provisions of the Declaration of Helsinki.

The primary goal of treatment was to improve exercise capacity, lung function, and to reduce symptoms of dyspnea. Secondary aims were to evaluate self-reported COPD symptoms and intake of relief medications and lung function variables such as Forced expiratory volume in 1 second (FEV1), Forced vital capacity(FVC).


  Patients and Methods Top


We enrolled 472 COPD patients above 65 years of age, among 620 patients who presented to the pulmonology department of our hospital during the year 2016–2018. One hundred and forty-eight patients were excluded from this study due to a history of right heart failure, severe diabetes, hypertension, and not willing to continue in this study. After explaining the protocol and benefits of this in their own language, written informed consent was obtained from all the participants for participation in the study as well as presentation of the data for research purposes.

All the consenting patients were investigated for COPD through routine tests (1) chest X-ray, (2) complete blood picture (CBP), (3) sputum bacterial culture sensitivity, and (4) pulmonary function tests (PFTs). The diagnosis of COPD was obtained by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria: The presence of a post-bronchodilator FEV1/FVC <0.70 confirms the presence of persistant airflow limitation. Most of the participants had at least one exacerbation in the past 6 months before screening. Mild-to-moderate COPD cases with exacerbations were enrolled in this study.

For the clinical and prognostic assessment of the patients, St. George's Respiratory Questionnaire (SGRQ) was used. This included assessment of the frequency of cough episodes, quantity of sputum/per day, baseline dyspnea index grading improvement, frequency of rotahalers use, and 6-min walk test (6MWD test).[4] CBP of the patients such as white cell count, neutrophils, eosinophils, monocytes, basophils, and erythrocyte sedimentation rate (ESR) was assessed. All the participants were from poor and lower middle-class background and most of them were daily Agricultural labourers and farmers. They were habituated to smoking cigars from a young age of 15 years.

Two hundred forty COPD patients were treated with 150 mg of theophylline, twice daily along with standard medication as per the GOLD guidelines, i.e., long-acting beta-2 agonists (LABA) + LAMA and ICSs rotahalers as the study group. Two hundred thirty-two participants were treated with only LABA + LAMA + ICS rotahalers and were considered as the control group.[5],[6] Two hundred micrograms of budesonide, 6 μg of formoterol fumarate, and 80 μg of ipratropium bromide dry powder inhalers were used due to their cheap availability. Their effect lasted up to 24 h. Single-blind method was used in this study because the use of placebo was not acceptable to the institutional ethical committee.

During the 30 days of the study period, all the participants were followed up every 10 days, i.e., three times in a month. At every follow-up, CBP, SGRQ, and PFTs were obtained again. In each visit, the patients were examined with respect to the correctness of inhalation technique and were advised as appropriate. Cigar smoking was completely banned.

DxH 800 (Beckman Cell Counter, Inc., Brea, CA, USA) blood analyzer was used for CBP. Jaeger Master Screen spirometer (Jaeger, Inc., Bodnegg, Germany) was used for PFTs.

The data are presented as a mean ± standard deviation. Comparison of continuous variables between two groups was done using unpaired “t”-test. Statistical significance was accepted if P < 0.05. All the statistical analysis was done by GraphPad Insat 3 software.


  Results Top


A total of 472 stable and eligible COPD patients underwent screening and enrolment to the study. The demographic and anthropometric characteristics of the patients and the use of respiratory medications were similar in both the study and control groups. The main characteristics of the subjects at the baseline are shown in [Table 1] and [Table 2].
Table 1: Clinical and demographic characteristics of participants

Click here to view
Table 2: St. George's Respiratory Questionnaire and pulmonary function tests of the study participants

Click here to view


After all the three follow-ups, the overall comparison of variables between both the groups throughout the whole study was performed. In the study group, on the 10th day of posttreatment, the prognostic factors such as CBP, indices of SGRQ, and PFTs were significantly improved as compared to the control group except FVC % (P = 0.0815) [Table 3] and [Table 4].
Table 3: Overall comparison of complete blood picture between the control group and study group

Click here to view
Table 4: Overall comparison of St. George's Respiratory Questionnaire and Pulmonary function tests between study group and control group

Click here to view


On the 20th day of the examination, significant improvement from the baseline characteristics was seen among the subjects who were treated with theophylline along with the routine treatment. A significant decrease in sputum volume and increase of 6MWD were also seen. In CBP, we observed a significant decrease in neutrophils, eosinophils, and ESR. PFTs (FEV1 and FEV1/FVC ratio) showed significant improvement in the study group than control, while there was no significant difference with respect of FVC% (P = 0.2164).

All the subjects were instructed to come for follow-up on the 30th day of treatment and were assessed as before. All the parameters in CBP were significantly improved in the study group than in the control group. The study group showed subjective improvement as assessed by St. George's respiratory criteria. Sputum volume was lower in the study group with minimal cough episodes. Pulmonary functions also improved significantly in the study group [Figure 1] and [Figure 2].
Figure 1: Comparison of pulmonary function tests between pre- and post-treatment among study group after a period of 30 days

Click here to view
Figure 2: Comparison of pulmonary function tests between pre- and post-treatment among control group after a period of 30 days

Click here to view



  Discussion Top


According to the GOLD guidelines 2019, controversy remains about the exact effects of xanthine derivatives. Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome p450 mixed-function oxidases. There is evidence for a modest bronchodilator effect compared with placebo in stable COPD. The addition of theophylline to salmeterol produces a greater improvement in FEV1 and breathlessness than salmeterol alone.[7] The addition of theophylline to salmeterol produces a greater improvement in FEV1 and breathlessness than salmeterol alone.[8] The GOLD 2018 and 2019 has recommended using the ABCD assessment tool for the treatment of COPD. However, GOLD 2019 has not included the preferred treatment algorithm. The initial treatment was streamlined, i.e., Group A: bronchodilator; Group B: LABA or LAMA; Group C: LAMA; and Group D: LAMA, LABA + LAMA or ICS + LABA. Single-inhaler triple therapy versus ICS plus LABA for COPD (TRILOGY) has been tried effectively.[9]

In this study, the primary effect of low-dose theophylline on CBP (white blood cell [WBC], eosinophil, neutrophils, monocytes, platelet count, and hemoglobin), St. George's respiratory indices, and PFTs (FVC, FEV1, and FEV1/FVC) of COPD patients was compared with patients treated without theophylline and the results were analyzed.

No significant improvement in PFTs of the participants was observed. However, blood parameters such as CBP, St. George's respiratory criteria, and daily life were significantly improved in the study group compared to the control group. Theophylline has an anti-inflammatory role in COPD. It inhibits cigarette smoke-induced inflammation in skeletal muscle by upregulating histone deacetylase 2 (HDAC2) expression and decreases NF-KB activation.[10] This can be explained by decreases in dyspnea, air trapping, and breathing difficulties and increases in diaphragmatic muscle contraction force with theophylline. It decreases the cough episodes as well as improvement in 6MWD. Markham and Faulds [10] reported that theophylline can reduce the eosinophil accumulation in bronchial tissue in the patients with asthma. Hirano et al.[11] confirmed that low-dose theophylline reduces the sputum neutrophils. Koo et al.[12] in Korea found a significant association between WBC and PFTs among COPD patients, especially noncurrently smoking COPD patients. A decrease in neutrophils was observed in the subjects who were treated with theophylline in this study. This suggests an anti-inflammatory effect of theophylline.

The fall in PFTs in the control group suggests that low-dose theophylline may not improve the PFTs, but it can decelerate the reduction in PFTs. Kirsten et al. found worsening of COPD control when theophylline was withdrawn.[13] Similar results were seen by Panahi et al., who assessed the effect of low-dose theophylline on the improvement of PFTs of sulfur mustard-exposed patients.[14]

The cumulative results of this study shown that a low-dose of theophylline can improve the COPD patients' symptoms, but it has minimal effect on the reversal of PFTs into normal. This can be explained by the findings of Gibson et al.[15] Theophylline shows its effect by restoring reduced HDAC activity to normal levels, thus suppressing inflammation and potentially making the COPD patients responsive to corticosteroids. Devereux et al.[16] demonstrated that low-dose theophylline increases the efficacy of corticosteroids in COPD by reducing the incidence of exacerbations.

In summary, despite an overall lack of benefit, approximately one-third of the patients were subjective responders in both dyspnea and FEV1 improvement. Selective phosphodiesterase –type 4 inhibito (PDE-4) inhibitors have potential to improve the beneficial effects of theophylline and reduce its adverse effects, although the existing inhibitors appear to be limited by the same side effects as theophylline. In the present study, slight FEV1 improvement was observed in the study group, but moderate obstruction was persisting with no change in peak expiratory flow rate. Cough episodes were reduced in the study group in 30 days. In the study group, 6 MWD test was improved up to 300 m compared to the control group. Dyspnea subsided in 30 days of treatment with theophylline in compared with control group, and sputum production was reduced significantly. In contrast to our results, other studies [16],[17],[18] found no beneficial effect. Further large-scale, long-duration study on a larger population is needed.


  Conclusion Top


Add-on therapy with theophylline improves the clinical condition and spirometric measurements of patients with COPD without an effect on peak expiratory flow rate. Quality of life improvement can be achieved by add-on therapy with theophylline along with ICS, long-acting beta agonists, and LAMA.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-95.  Back to cited text no. 1
    
2.
To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:897-904.  Back to cited text no. 2
    
3.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease; 2019. Available from: https://goldcopd.org/wp-content/uploads/2019/04/GOLD_Spirometry_2019.pdf. [Last accessed on 2019 Aug 24].  Back to cited text no. 3
    
4.
Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991;85 Suppl B: 25-31.  Back to cited text no. 4
    
5.
Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet 2004;364:791-802.  Back to cited text no. 5
    
6.
Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350:2689-97.  Back to cited text no. 6
    
7.
Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4:CD003902.  Back to cited text no. 7
    
8.
ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70.  Back to cited text no. 8
    
9.
Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-73.  Back to cited text no. 9
    
10.
Markham A, Faulds D. Theophylline. A review of its potential steroid sparing effects in asthma. Drugs 1998;56:1081-91.  Back to cited text no. 10
    
11.
Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, et al. Inhibition of reactive nitrogen species production in COPD airways: Comparison of inhaled corticosteroid and oral theophylline. Thorax 2006;61:761-6.  Back to cited text no. 11
    
12.
Koo HK, Kang HK, Song P, Park HK, Lee SS, Jung H, et al. Systemic white blood cell count as a biomarker associated with severity of chronic obstructive lung disease. Tuberc Respir Dis (Seoul) 2017;80:304-10.  Back to cited text no. 12
    
13.
Kirsten DK, Wegner RE, Jörres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993;104:1101-7.  Back to cited text no. 13
    
14.
Panahi Y, Poursaleh Z, Amini-Harandi A, Powel H, Walters EH. Study on effectiveness of low dose theophylline as add-on to inhaled corticosteroid for patients with sulfur mustard induced bronchiolitis. Asia Pac J Med Toxicol 2013;2:126-30.  Back to cited text no. 14
    
15.
Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2000;(2):CD001117.  Back to cited text no. 15
    
16.
Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: Study protocol for a randomised controlled trial. Trials 2015;16:267.  Back to cited text no. 16
    
17.
Waterhouse JC, Pritchard SM, Howard P. Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1993;48:126-9.  Back to cited text no. 17
    
18.
McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax1993;48:227-32.  Back to cited text no. 18
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Patients and Methods
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed466    
    Printed28    
    Emailed0    
    PDF Downloaded75    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]